Immatics Other Current Assets from 2010 to 2024

IMTXW Stock  USD 0.41  0.01  2.38%   
Immatics Biotechnologies Other Current Assets yearly trend continues to be fairly stable with very little volatility. Other Current Assets are likely to outpace its year average in 2024. Other Current Assets is assets expected to be converted into cash, sold, or consumed either in one year or in the operating cycle, which are not included under standard current asset categories. View All Fundamentals
 
Other Current Assets  
First Reported
2019-03-31
Previous Quarter
24.4 M
Current Value
13.9 M
Quarterly Volatility
7.7 M
 
Covid
Check Immatics Biotechnologies financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immatics Biotechnologies' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Net Interest Income of 13.7 M or Interest Income of 14.5 M, as well as many indicators such as Price To Sales Ratio of 13.5, Dividend Yield of 0.0 or PTB Ratio of 3.58. Immatics financial statements analysis is a perfect complement when working with Immatics Biotechnologies Valuation or Volatility modules.
  
Check out the analysis of Immatics Biotechnologies Correlation against competitors.

Latest Immatics Biotechnologies' Other Current Assets Growth Pattern

Below is the plot of the Other Current Assets of immatics biotechnologies GmbH over the last few years. It is assets expected to be converted into cash, sold, or consumed either in one year or in the operating cycle, which are not included under standard current asset categories. Immatics Biotechnologies' Other Current Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Immatics Biotechnologies' overall financial position and show how it may be relating to other accounts over time.
Other Current Assets10 Years Trend
Slightly volatile
   Other Current Assets   
       Timeline  

Immatics Other Current Assets Regression Statistics

Arithmetic Mean4,309,393
Geometric Mean1,619,655
Coefficient Of Variation150.71
Mean Deviation4,888,444
Median665,000
Standard Deviation6,494,572
Sample Variance42.2T
Range18M
R-Value0.78
Mean Square Error18.1T
R-Squared0.60
Significance0.0007
Slope1,126,451
Total Sum of Squares590.5T

Immatics Other Current Assets History

202418.6 M
202317.7 M
202212.8 M
20214.7 M
20204.1 M

About Immatics Biotechnologies Financial Statements

Immatics Biotechnologies investors use historical fundamental indicators, such as Immatics Biotechnologies' Other Current Assets, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Immatics Biotechnologies. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Other Current Assets17.7 M18.6 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Immatics Stock Analysis

When running Immatics Biotechnologies' price analysis, check to measure Immatics Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immatics Biotechnologies is operating at the current time. Most of Immatics Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Immatics Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immatics Biotechnologies' price. Additionally, you may evaluate how the addition of Immatics Biotechnologies to your portfolios can decrease your overall portfolio volatility.